Lymphocytic colitis is a subtype of microscopic colitis, a condition characterized by chronic non-bloody watery diarrhea.

No definite cause has been determined. The peak incidence of lymphocytic colitis is in persons over age 50; the disease affects women and men equally. Some reports have implicated long-term usage of NSAIDs, proton pump inhibitors, and selective serotonin reuptake inhibitors, and other drugs. Associations with other autoimmune disorders suggest that overactive immune responses occur.

The colonoscopy is normal but histology of the mucosal biopsy reveals an accumulation of lymphocytes in the colonic epithelium and connective tissue (lamina propria). Collagenous colitis shares this feature but additionally shows a distinctive thickening of the subepithelial collagen table.

Budesonide, in colonic release preparations, has been shown in randomized controlled trials to be effective in treating this disorder. It helps control the diarrheal symptoms and treatment is usually given for several weeks. Sometimes it is used to prevent frequent relapses.

Over-the-counter antidiarrheal drugs may be effective for some people with lymphocytic colitis. Anti-inflammatory drugs, such as salicylates, mesalazine, and systemic corticosteroids may be prescribed for people who do not respond to other drug treatment. The long-term prognosis for this disease is good with a proportion of people suffering relapses which respond to treatment.

Journal of Inflammatory Bowel Diseases & Disorders brings articles in all areas related to inflammatory bowel disease, inflammatory bowel disease treatment, abdominal pain, collagenous colitis, lymphocytic colitis, diversion colitis, colon cancer, colon failure, colon disorders, intestinal endometria, bowel endometriasis, crohn's disease, celiac disease, bowel cancer, etc.

It’s our privilege to recite you as a foremost strategist in the realm of research and invite to endowment your research penmanship to write (volume 6 issue 3) Short Communication or mini review on above topic to be published in our journal.

Our Journal follows Editorial Tracking System for quality in peer review process. Editorial Tracking is an online manuscript submission, review and tracking systems used by most of the best open access journals.

Submit manuscripts at: https://www.scholarscentral.org/submissions/inflammatory-bowel-diseases-disorders.html

Media Person

Mercedes Rose
Journal Coordinator
Journal of Inflammatory Bowel Diseases and Disorders
ISSN: 2476-1958